Long-acting growth hormone
:Growth disorder
:Phase 2
Novo Nordisk is developing a long acting human growth hormone analogue designed for once-weekly treatment. The product is intended to improve patient convenience by reducing the number of injections needed.
- Company announcements
- Major shareholder notification (07 Nov 2008)
- Novo Nordisk A/S purchases B shares worth DKK 1.0 billion from Novo A/S as part of the ongoing share repurchase programme (14 Aug 2008)
- Significant weight loss sustained in obese people treated with liraglutide for one year (16 Jun 2008)
- Read more company announcements
- Press releases
- New study results show that patients have higher treatment satisfaction with liraglutide compared to exenatide (22 Oct 2009)
- The 4-T study of intensified insulin regimens shows excellent three-year glucose control with low risk of hypoglycaemia in type 2 diabetes (22 Oct 2009)
- Two-year data show investigational drug liraglutide more effective at lowering blood sugar than glimepiride (07 Jun 2009)
- Read more press releases
- Scientific abstracts
- Diabetes (2000)
- Journal of Endocrinology (2006)
- Read more scientific abstracts
